![Reaction of X and phenylacetic acid forms an intermediate Y, which undergoes an intramolecular reaction to yield rofecoxib. Rofecoxib is a nonsteroidal anti-inflammatory agent once marketed under the trade name Vioxx, now Reaction of X and phenylacetic acid forms an intermediate Y, which undergoes an intramolecular reaction to yield rofecoxib. Rofecoxib is a nonsteroidal anti-inflammatory agent once marketed under the trade name Vioxx, now](https://homework.study.com/cimages/multimages/16/likun77363469449483666814.png)
Reaction of X and phenylacetic acid forms an intermediate Y, which undergoes an intramolecular reaction to yield rofecoxib. Rofecoxib is a nonsteroidal anti-inflammatory agent once marketed under the trade name Vioxx, now
![Draw the electron-pushing mechanism for the propagation steps of the allylic bromination reaction below. You may omit NBS in your mechanism and use Br-cdot and Br2. | Homework.Study.com Draw the electron-pushing mechanism for the propagation steps of the allylic bromination reaction below. You may omit NBS in your mechanism and use Br-cdot and Br2. | Homework.Study.com](https://homework.study.com/cimages/multimages/16/6692426-a8460541815119574233.png)
Draw the electron-pushing mechanism for the propagation steps of the allylic bromination reaction below. You may omit NBS in your mechanism and use Br-cdot and Br2. | Homework.Study.com
![PDF) Stereochemistry. XXXIV. Nitro compounds. 7. Chemistry of 3-oxo-2-phenylindolenine | Alfred Hassner - Academia.edu PDF) Stereochemistry. XXXIV. Nitro compounds. 7. Chemistry of 3-oxo-2-phenylindolenine | Alfred Hassner - Academia.edu](https://0.academia-photos.com/attachment_thumbnails/47135227/mini_magick20190207-27901-tprgq9.png?1549590736)
PDF) Stereochemistry. XXXIV. Nitro compounds. 7. Chemistry of 3-oxo-2-phenylindolenine | Alfred Hassner - Academia.edu
![Molecules | Free Full-Text | 8-Oxo-7,8-Dihydro-2′-Deoxyguanosine (8-oxodG) and 8-Hydroxy-2′-Deoxyguanosine (8-OHdG) as a Potential Biomarker for Gestational Diabetes Mellitus (GDM) Development Molecules | Free Full-Text | 8-Oxo-7,8-Dihydro-2′-Deoxyguanosine (8-oxodG) and 8-Hydroxy-2′-Deoxyguanosine (8-OHdG) as a Potential Biomarker for Gestational Diabetes Mellitus (GDM) Development](https://pub.mdpi-res.com/molecules/molecules-25-00202/article_deploy/html/images/molecules-25-00202-ag-550.jpg?1579226161)
Molecules | Free Full-Text | 8-Oxo-7,8-Dihydro-2′-Deoxyguanosine (8-oxodG) and 8-Hydroxy-2′-Deoxyguanosine (8-OHdG) as a Potential Biomarker for Gestational Diabetes Mellitus (GDM) Development
![PDF) Structure–function characterization of an aldo–keto reductase involved in detoxification of the mycotoxin, deoxynivalenol PDF) Structure–function characterization of an aldo–keto reductase involved in detoxification of the mycotoxin, deoxynivalenol](https://i1.rgstatic.net/publication/363107827_Structure-function_characterization_of_an_aldo-keto_reductase_involved_in_detoxification_of_the_mycotoxin_deoxynivalenol/links/630e20bb61e4553b954e1337/largepreview.png)
PDF) Structure–function characterization of an aldo–keto reductase involved in detoxification of the mycotoxin, deoxynivalenol
![P450 inhibitor ketoconazole increased the intratumor drug levels and antitumor activity of fenretinide in human neuroblastoma xenograft models - Lopez‐Barcons - 2017 - International Journal of Cancer - Wiley Online Library P450 inhibitor ketoconazole increased the intratumor drug levels and antitumor activity of fenretinide in human neuroblastoma xenograft models - Lopez‐Barcons - 2017 - International Journal of Cancer - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/68a1cc32-155d-4f6c-a8b3-bb350037ca04/ijc30706-fig-0002-m.jpg)
P450 inhibitor ketoconazole increased the intratumor drug levels and antitumor activity of fenretinide in human neuroblastoma xenograft models - Lopez‐Barcons - 2017 - International Journal of Cancer - Wiley Online Library
![Targeting KRAS Mutant Cancers via Combination Treatment: Discovery of a Pyridopyridazinone pan-RAF Kinase Inhibitor | ACS Medicinal Chemistry Letters Targeting KRAS Mutant Cancers via Combination Treatment: Discovery of a Pyridopyridazinone pan-RAF Kinase Inhibitor | ACS Medicinal Chemistry Letters](https://pubs.acs.org/cms/10.1021/acsmedchemlett.1c00063/asset/images/medium/ml1c00063_0007.gif)